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Introduction {#sec1}
============

Embryonic stem cells and induced pluripotent stem cells (iPSCs) can differentiate into neural stem/progenitor cells (NS/PCs), which can subsequently be induced in vitro to differentiate into three neural lineages: neurons, astrocytes, and oligodendrocytes ([@bib5], [@bib14], [@bib20]). Furthermore, accumulating evidence suggests that NS/PCs represent a promising cell source for regenerative medicine targeting CNS disorders ([@bib4], [@bib8], [@bib9], [@bib12], [@bib16], [@bib21], [@bib22], [@bib18], [@bib26], [@bib28]). Our previous reports have shown that transplantation of NS/PCs derived from human induced pluripotent stem cells (hiPSC-NS/PCs) promotes motor function recovery in non-obese diabetic-severe combined immune-deficient (NOD-SCID) mice and non-human primates with spinal cord injury (SCI) ([@bib6], [@bib10], [@bib16], [@bib23], [@bib27]). However, transplanting certain hiPSC-NS/PCs, such as clone 253G1 (generated through a process of retroviral transfection), results in tumor-like overgrowth and deterioration of motor function during long-term observations ([@bib17]), and transplanting clone 836B3 (episomal plasmid vectors) in an SCI animal model yielded similar results during long-term observations (our unpublished data). Moreover, these tumors consisted of undifferentiated human-specific Nestin^+^ cells.

The safety of measures for preventing tumor-like overgrowth is of great importance in clinical applications of iPSC-based transplantation therapy for SCI. Remnant immature NS/PCs must be removed or induced to differentiate into more mature cell types, which may avoid tumor-like overgrowth following transplantation. Notch signaling controls the induction of NS/PCs, and inhibition of this signaling with a γ-secretase inhibitor (GSI) induces the NS/PCs to develop into a more mature state with limited proliferation in vitro ([@bib3], [@bib15]). Treatment of iPSC-derived dopaminergic progenitor cells with GSIs prior to transplantation into the normal mid-striatum is known to control the growth of a potentially proliferative cell population in vivo ([@bib19]).

The purpose of the present study was to elucidate the effects of a GSI on the proliferation and differentiation of tumorigenic hiPSC-NS/PCs in vitro, assess the effects of GSI pretreatment on the hiPSC-NS/PCs in vivo, and determine whether animal models of SCI exhibit recovered motor functions and an absence of tumor-like overgrowth following transplantation of the pretreated cells.

Results {#sec2}
=======

Treatment with the GSI Suppressed the Proliferation of hiPSC-NS/PCs {#sec2.1}
-------------------------------------------------------------------

We performed differentiation and proliferation assays using hiPSC-NS/PCs in vitro. After treating the cells with or without GSI, aggregated hiPSC-NS/PCs were dissociated into single cells and the living cells were counted. In the GSI-4d group (hiPSC-NS/PCs cultured in vitro with GSI for 4 days), the number of living cells was significantly decreased compared with that of the other groups (253G1: control 1.14 × 10^6^ cells, GSI-1d \[hiPSC-NS/PCs cultured in vitro with GSI for 1 day\] 9.80 × 10^5^ cells, GSI-4d 7.28 × 10^5^ cells; 836B3: control 1.51 × 10^6^ cells, GSI-1d 1.31 × 10^6^ cells, GSI-4d, 8.42 × 10^5^ cells; [Figure 1](#fig1){ref-type="fig"}A). Next, the size of the sphere was measured by microscopy after treatment with or without GSI. In the control group, the size of the sphere was significantly increased compared with that of both GSI groups (253G1: control 394.7 ± 69.5 μm, GSI-1d 224.1 ± 46.1 μm, GSI-4d 220.4 ± 17.3 μm; 836B3: control 155.2 ± 10.7 μm, GSI-1d 110.4 ± 23.6 μm, GSI-4d 105.9 ± 21.8 μm; [Figures 2](#fig2){ref-type="fig"}B and 2C).

In the cell-cycle analyses, representative dot plots of the flow cytometry data revealed a reduced S-phase population among the GSI-treated hiPSC-NS/PCs ([Figure 1](#fig1){ref-type="fig"}D). Compared with the control group, the proportion of cells in G~0~/G~1~ phase was significantly increased (253G1: control 62.6% ± 2.7%, GSI-1d 72.8% ± 1.1%, GSI-4d 74.8% ± 1.8%; 836B3: control 58.9% ± 1.3%, GSI-1d 74.4% ± 2.3%, GSI-4d 75.7% ± 2.9%). The proportion of cells in the S phase was significantly decreased in both GSI groups (253G1: control 18.6% ± 0.8%, GSI-1d 4.1% ± 0.2%, GSI-4d 3.6% ± 0.1%; 836B3: control 33.8% ± 0.9%, GSI-1d 9.6% ± 0.6%, GSI-4d 11.2% ± 1.2%; [Figure 1](#fig1){ref-type="fig"}E). According to the annexin V/7-AAD apoptosis assay, the proportion of early apoptotic cells was slightly increased in both GSI groups compared with the control group, although significant differences were not observed among these groups (253G1: control 2.01% ± 0.2%, GSI-1d 4.1% ± 0.3%, GSI-4d 5.5% ± 0.4%; 836B3: control 2.0% ± 0.5%, GSI-1d 3.1% ± 0.3%, GSI-4d 4.7% ± 0.5%). These results suggest that GSI treatment could induce the differentiation of undifferentiated hiPSC-NS/PCs.

GSI Induced Differentiation into More Mature Neuronal Cell Types with Limited Cell Proliferation {#sec2.2}
------------------------------------------------------------------------------------------------

Next, we assessed the effects of GSI on the neuronal differentiation and maturation of hiPSC-NS/PCs. In both GSI groups, the proportion of Ki-67^+^ (a cell proliferation marker) and Nestin^+^ (a neural stem cell marker) cells was also significantly decreased compared with that of the control group (Ki-67^+^ cells: 253G1---control 45.2% ± 1.4%, GSI-1d 30.7% ± 2.2%, GSI-4d 28.1% ± 0.8%; 836B3---control 34.0% ± 2.7%, GSI-1d 16.7% ± 1.9%, GSI-4d 13.0% ± 1.7%; Nestin^+^ cells: 253G1---control 60.8% ± 1.9%, GSI-1d 36.6% ± 1.2%, GSI-4d 30.9% ± 1.4%; 836B3---control 43.6% ± 2.1%, GSI-1d 34.1% ± 0.5%, GSI-4d 23.6% ± 1.1%; [Figures 2](#fig2){ref-type="fig"}A--2D), whereas the proportion of βIII-tubulin^+^ neurons was significantly increased (253G1: control 70.9% ± 2.3%, GSI-1d 94.7% ± 3.1%, GSI-4d 94.3% ± 2.4%; 836B3: control 47.6% ± 4.8%, GSI-1d 86.0% ± 4.9%, GSI-4d 86.7% ± 5.0%). The proportion of GFAP^+^ astrocytes and CNPase^+^ (2′,3′-cyclic-nucleotide 3′-phosphodiesterase) oligodendrocytes was not significantly different among the three groups ([Figures 2](#fig2){ref-type="fig"}E--2H). Microelectrode array (MEA) analyses indicated that neuronal maturation was significantly enhanced in both GSI groups compared with the control group ([Figure 2](#fig2){ref-type="fig"}J).

Gene Expression Profiles of hiPSC-NS/PCs after the GSI Treatment {#sec2.3}
----------------------------------------------------------------

DNA microarray analyses were performed on the hiPSC-NS/PCs that were treated with or without GSI to evaluate the gene expression profiles of the cells. Following the GSI treatment, 61 genes were downregulated (downregulation: 97 genes in the GSI-1d group, 274 genes in the GSI-4d group; [Figure 3](#fig3){ref-type="fig"}A) and 53 genes were upregulated (upregulation: 58 genes in the GSI-1d group, 147 genes in the GSI-4d group; [Figure 3](#fig3){ref-type="fig"}B) in 253G1 hiPSC-NS/PCs. In 836B3 hiPSC-NS/PCs, 26 genes were downregulated (downregulation: 49 genes in the GSI-1d group, 63 genes in the GSI-4d group; [Figure 3](#fig3){ref-type="fig"}C) and seven genes were upregulated (upregulation: eight genes in the GSI-1d group, 77 genes in the GSI-4d group; [Figure 3](#fig3){ref-type="fig"}D). Functional association analyses showed that the expression of cell-cycle-related genes and more mature neuronal marker-related genes increased by \>2-fold in both GSI groups compared with the control group. Significant increases in the levels of p53-dependent genes, such as *CDKN1C* and *GADD45G*, and more neuronal maturation-dependent genes, such as *NEUROG1*, *NEUROD1*, and *ASCL1*, were detected ([Figures 3](#fig3){ref-type="fig"}E and 3F).

Gene Ontology (GO) analyses identified a number of neuronal differentiation- and maturation-associated terms, such as "neuron differentiation," "neuron development," "developmental maturation," "regulation of cell cycle," and "neuron projection development," in the GSI-treated hiPSC-NS/PCs ([Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}).

We performed RT-PCR to validate these findings, which showed that the expression of representative Notch signaling target genes, such as *HES5* and *NOTCH1*, was nearly abolished by pretreatment with GSI ([Figure S1](#mmc1){ref-type="supplementary-material"}A). In addition, the expression of early neural marker genes, such as *SOX2* and *PAX6*, was also downregulated in both GSI groups. The expression of mature neuronal marker genes, such as *NEUROG2*, *ASCL1*, and *NEUROD1* (but not glial markers, such as *GFAP* and *OLIG2*), was upregulated, as expected, given the downregulated expression of pluripotency/self-renewal markers, such as *NANOG*, *LIN28*, *OCT4*, and *NESTIN* ([Figures S1](#mmc1){ref-type="supplementary-material"}B--S1D).

Next, we confirmed the role of Notch signaling in the specification of hiPSC-NS/PCs by comparing the qRT-PCR analyses for each cell line after treatment with or without GSI. The data were presented as expression levels relative to the 836B3 hiPSC-NS/PCs. The expression of Notch signaling-related genes, such as *JAGGED1*, *NOTCH1*, and *PSEN1*, was significantly upregulated in the 253G1 hiPSC-NS/PCs, which seemed to indicate that Notch signaling was increased in the 253G1 hiPSC-NS/PCs compared with the 836B3 hiPSC-NS/PCs. Under these activation conditions, the expression of the *HES5*, *HEYL*, *HSPB1*, *ID2*, *ID4*, *NESTIN*, *OCT3*/*4*, *VCAM1*, and *NANOG* genes were particularly downregulated in the GSI-treated groups compared with the control group. Additionally for each cell line, the GSI treatment resulted in a decrease in the expression of the target genes of Notch signaling, such as *JAGGED1* and *NRARP* ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B).

Previous transcriptome analyses by our group revealed the altered expression of genes involved in epithelial-mesenchymal transition (EMT), which plays roles in tumor invasion and progression, following the transplantation of 253G1 hiPSC-NS/PCs ([@bib17]). The expression of EMT-related genes, such as *SNAIL1*, *SNAIL2*, *TWIST1*, and *TWIST2*, was downregulated in the GSI-treated group compared with the control group ([Figure 3](#fig3){ref-type="fig"}G).

Long-Term Observations after Transplantation of Tumorigenesis-/Overgrowth-Prone hiPSC-NS/PCs that Had Been Pretreated with GSI {#sec2.4}
------------------------------------------------------------------------------------------------------------------------------

Next, we examined the long-term effects of GSI pretreatment on hiPSC-NS/PCs that had been transplanted into SCI model mice in vivo and focused on the potency of the GSI treatment in preventing the tumor-like overgrowth of the graft-derived cells. A previous study by our group showed that 253G1 hiPSC-NS/PCs are characterized by tumor-like overgrowth following cell transplantation in the injured spinal cord of NOD/SCID mice ([@bib17]). In fact, 253G1 hiPSC-NS/PCs tended to grow and spread at a faster rate than 836B3 hiPSC-NS/PC transplants (our unpublished data). Here, we found that inhibiting Notch signaling with the GSI promoted the neuronal differentiation and maturation of hiPSC-NS/PCs in vitro, irrespective of the culture period and the cell line ([Figure 2](#fig2){ref-type="fig"}). Thus, we pretreated the 253G1 hiPSC-NS/PCs with the GSI for 1 day before cell transplantation. To monitor the survival and growth of the transplanted cells in the mouse injured spinal cord, we lentivirally transduced the hiPSC-NS/PCs with ffLuc, a fusion protein between a fluorescent protein Venus and a firefly luciferase ([@bib7]), which allowed us to identify the transplanted cells by their bioluminescent luciferase signals and fluorescent Venus signals. The photon counts and the number of the hiPSC-NS/PCs were significantly correlated (r^2^ = 0.998, [Figures S3](#mmc1){ref-type="supplementary-material"}A--S3C). The photon counts of the transplanted hiPSC-NS/PCs decreased within the first 7 days, although they gradually increased at 14 days after cell transplantation. In the control group, the photon counts were prominently increased compared with that of the GSI^+^ group between 28 and 89 days after cell transplantation ([Figures 4](#fig4){ref-type="fig"}A and 4B). The photon counts of the control group increased more than 10-fold from their initial values at 89 days after cell transplantation. In the GSI^+^ group, the photon counts increased more slowly and reached a plateau at 28 days after cell transplantation. Representative results of H&E staining of spinal cords from the control group and the GSI^+^ group after injury and transplantation are shown in [Figure 4](#fig4){ref-type="fig"}C. In the control group, the HNA^+^ transplanted cells occupied the entire spinal cord, whereas the cells in the GSI^+^ group did not. The volumes and sizes of the grafts that were pretreated with GSI were significantly smaller than the grafts in the control group (volume of grafts: control group 7.3 ± 1.5 mm^2^, GSI^+^ group 1.3 ± 0.6 mm^2^; [Figures 4](#fig4){ref-type="fig"}D and 4E). After transplantation into the injured spinal cord, the transplanted hiPSC-NS/PCs differentiated into three neural lineages in each group, such as pan-ELAVL (Hu)^+^ neurons, GFAP^+^ astrocytes, and APC^+^ oligodendrocytes. We also detected the Ki-67^+^ and Nestin^+^ cells ([Figure 4](#fig4){ref-type="fig"}F). Immunostaining for various cell markers was examined 89 days after transplantation and subjected to quantitative analyses to evaluate the differentiation phenotype of the transplanted cells in vivo. The proportion of pan-ELAVL (Hu)^+^ cells was significantly increased (control group 15.6% ± 1.2%, GSI^+^ group 51.0% ± 1.8%) in the GSI^+^ group, although the proportion of Ki-67^+^ cells (control group 17.9^+^ ± 0.9%, GSI^+^ group 3.9% ± 0.9%) and that of Nestin^+^ cells (control group 30.3% ± 1.6%, GSI^+^ group 5.3% ± 0.8%) were also significantly decreased compared with the control group. The proportion of GFAP^+^ cells (control group 15.6% ± 1.1%, GSI^+^ group 11.5% ± 3.9%) and that of APC^+^ cells (control group 5.2^+^ ± 1.1%, GSI^+^ group 4.2% ± 1.0%) were not significantly different between the control group and the GSI^+^ group ([Figure 4](#fig4){ref-type="fig"}G).

We examined triple immunostaining with HNA, βIII-tubulin, and mouse-specific Bassoon (Bsn), a presynaptic marker, to evaluate the ability of the GSI-pretreated transplanted cell-derived neurons to integrate with host neural circuitry. βIII-tubulin^+^/HNA^+^ cells that were transplanted in parenchymal locations were contacted by Bsn^+^ synaptic boutons of the host neurons ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Moreover, triple immunostaining for HNA, βIII-tubulin, and human-specific synaptophysin (hSyn) revealed that hSyn^+^ boutons apposed the host mouse neurons (βIII-tubulin^+^/HNA^−^) ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Furthermore, immunostaining for Notch1, activated Notch1, and Snail were examined 89 days after transplantation and subjected to quantitative analyses to confirm the level of Notch activation and EMT in the transplanted cells in vivo. In the GSI^+^ group, the proportion of Notch1^+^ cells (control group 43.1% ± 7.2%, GSI^+^ group 2.5% ± 2.3%), activated Notch1^+^ cells (control group 34.1% ± 3.2%, GSI^+^ group 0.55% ± 0.35%), and Snail^+^ cells (control group 36.7% ± 5.1%, GSI^+^ group 0%) were all significantly decreased compared with that of the control group ([Figures 5](#fig5){ref-type="fig"}A--5F).

Transplantation of Tumorigenesis-/Overgrowth-Prone hiPSC-NS/PCs Pretreated with GSI Maintains Motor Functional Recovery after SCI {#sec2.5}
---------------------------------------------------------------------------------------------------------------------------------

We evaluated locomotor function using the Basso Mouse Scale (BMS) score, rotarod testing, and treadmill gait analyses with the DigiGait system. In the control group, the recovery of motor function persisted for up to 35 days after transplantation, although thereafter hindlimb motor function exhibited gradual deterioration according to the BMS score. In the GSI^+^ group, significantly greater functional recovery was observed relative to the PBS group and the control group at 42 days after transplantation and was maintained thereafter ([Figure 6](#fig6){ref-type="fig"}A). The gait performance of the mice in each group was analyzed using the rotarod test and the DigiGait system at 89 days after transplantation. In the GSI^+^ group, the mice remained on the rotating rod for a significantly longer time than the mice in the PBS group and the control group ([Figure 6](#fig6){ref-type="fig"}B), and all of the mice could sufficiently walk on a treadmill at 7 cm/s to perform the test. The gait analyses also revealed a significantly longer stride length in the GSI^+^ group than in the PBS and control groups ([Figure 6](#fig6){ref-type="fig"}C).

Transplantation of Normal/Safe hiPSC-NS/PCs Pretreated with GSI Survive and Enhance Motor Functional Recovery Following SCI {#sec2.6}
---------------------------------------------------------------------------------------------------------------------------

Finally, we elucidated the long-term effects of GSI pretreatment on normal/safe hiPSC-NS/PCs that were transplanted into SCI model mice. Our group previously showed that 201B7 hiPSC-NS/PCs are "normal/safe" cell lines that did not display tumor-like overgrowth following transplantation in the injured spinal cord of NOD/SCID mice ([@bib16], [@bib17]). We transplanted 201B7 hiPSC-NS/PCs with and without GSI treatment and examined their behavior after transplantation. The photon counts reached a plateau at 14 days after cell transplantation in each group ([Figures 7](#fig7){ref-type="fig"}A and 7B). The volume and size of the grafts were not significantly different between the control group and the GSI^+^ group (graft volume: control group 2.2 ± 0.5 mm^2^, GSI^+^ group 2.1 ± 0.5 mm^2^; [Figures 7](#fig7){ref-type="fig"}C--7E). In each group, the transplanted hiPSC-NS/PCs survived and did not cause tumor-like overgrowth. We examined the effects of transplantation for hiPSC-NS/PCs with and without GSI treatment on axonal regrowth after SCI by immunostaining analyses. More neurofilament 200-kDa-positive neuronal fibers and 5-hydroxytryptamine-positive serotonergic fibers were observed in the GSI^+^ group than in the PBS and control groups ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). In the GSI^+^ group, there were also significantly more growth-associated protein 43-positive fibers in the ventral region 1 mm caudal to the lesion epicenter than in the PBS and control groups ([Figures S5](#mmc1){ref-type="supplementary-material"}C and S5D).

The recovery of motor function persisted for up to 89 days after transplantation in each group compared with the PBS group. Furthermore, in the GSI^+^ group, significantly greater functional recovery occurred compared with the control group at 35 days after transplantation ([Figure 7](#fig7){ref-type="fig"}F). In the GSI^+^ group, the mice remained on the rotating rod for a significantly longer time those in the PBS and control groups ([Figure 7](#fig7){ref-type="fig"}G). In the treadmill gait analyses, significant differences were not observed in stride length between the control group and the GSI^+^ group ([Figure 7](#fig7){ref-type="fig"}H).

Discussion {#sec3}
==========

In the present study, we report seven major findings. First, after the hiPSC-NS/PCs were treated with the GSI, the number of cells, the size of neurospheres, the proportion of cells in the S phase of the cell cycle, and the number of Ki-67^+^ and Nestin^+^ cells determined by immunostaining were all significantly decreased compared with that of the control group. Second, the proportion of βIII-tubulin^+^ neuronal cells was significantly increased in the GSI-treated group compared with the control ([Figure 1](#fig1){ref-type="fig"}), and an MEA assay showed that the average number of active electrodes occurred significantly earlier and exhibited much more neuronal activity than the control group ([Figure 2](#fig2){ref-type="fig"}J). Third, the gene expression profiles of the GSI-treated hiPSC-NS/PCs obtained from the DNA microarray and RT-PCR showed that the expression of cell-cycle-related genes, mature neuronal marker-related genes, and p53-dependent genes was increased compared with that of the control group, which is consistent with decreases in pluripotency and self-renewal marker genes ([Figure 3](#fig3){ref-type="fig"}). Fourth, after transplantation of the hiPSC-NS/PCs in animal models of SCI, the photon counts of the transplanted cells increased more slowly and reached a plateau at 28 days in the GSI^+^ groups as determined by bioluminescence (BLI) ([Figures 4](#fig4){ref-type="fig"}A and 4B). Fifth, in the GSI^+^ group, the proportion of pan-ELAVL (Hu)^+^ cells was significantly increased, although the proportion of Ki-67^+^ cells, Nestin^+^ cells, Notch1^+^ cells, activated Notch1^+^ cells, and Snail^+^ cells was significantly decreased compared with that of the control group ([Figures 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}). Sixth, in the long-term observations, the control group showed deteriorated motor function accompanied by tumor-like overgrowth. However, the GSI^+^ group maintained functional recovery and reduced the overgrowth of transplanted cells by inhibiting cell proliferation ([Figure 6](#fig6){ref-type="fig"}). Seventh, after transplantation of a normal/safe cell line, the grafts that were pretreated with GSI also survived and did not show tumor-like overgrowth, which caused motor functional recovery after SCI ([Figure 7](#fig7){ref-type="fig"}). Taken together, these results suggest that the GSI treatment induces the differentiation of hiPSC-NS/PCs into a more mature state with limited proliferation and contributes to functional recovery without tumor-like overgrowth in the injured spinal cord. We believe that this strategy improves the safety of hiPSC-NS/PC transplantation therapy for SCI.

Previous studies have reported that Notch signaling controls the induction of neural stem cells in vitro and in vivo during differentiation ([@bib3], [@bib15]). As established by [@bib19], inhibition of this signaling pathway promotes the neuronal differentiation of neural progenitor cells derived from human iPSCs. Our in vitro experiments confirmed that by inhibiting Notch signaling with the GSI, a greater number of NS/PCs derived from two lines of human iPSCs with tumorigenesis-/overgrowth-prone characters (253G1 and 836B3) are induced to undergo neuronal differentiation and maturation, although they present limited proliferation.

[@bib15] showed treatments with a GSI (DAPT) lasting at least 6 hr commits NS/PCs to neuronal differentiation, although *HES5* expression is reduced after 3 hr. In the present study, significant differences were not observed between the GSI-1d and GSI-4d group in hiPSC-NS/PC proliferation and differentiation, suggesting that inhibition of Notch signaling with a GSI promotes the neuronal differentiation and maturation of hiPSC-NS/PCs regardless of the culture period or cell lines.

[@bib16] showed that the 201B7 hiPSC-NS/PC-transplanted group exhibited significantly better functional recovery than the PBS-injected group more than 21 days after SCI as measured by the BMS score. In this study, the GSI^+^ group of 253G1 hiPSC-NS/PC transplants ("bad" clone) exhibited confirmed functional recovery more than 21 days after SCI (BMS score: PBS group 2.5 ± 0.3 at 12 days post transplantation and 3.0 ± 0.1 at 89 days post transplantation; GSI^+^ group 3.8 ± 0.7 at 12 days post transplantation and 4.8 ± 0.4 at 89 days post transplantation). [@bib2] showed that the neural stem cell derived from human embryonic cells pretreated with DAPT were strongly positive for human synaptophysin, and exhibited strong human doublecortin staining compared with untreated cells after transplantation. In this study, the GSI^+^ group of 201B7 hiPSC-NS/PC transplants ("good" clone) exhibited a significantly greater tendency to enhance the axonal regrowth in the mouse injured spinal cord, which are likely to have resulted in improved motor function compared with the control group at 26 days after transplantation. The improved motor function was maintained after this point in the GSI^+^ group (BMS score: control group 3.8 ± 0.2 at 26 days post transplantation and 4.4 ± 0.5 at 89 days post transplantation; GSI^+^ group 4.3 ± 0.5 at 26 days post transplantation and 4.9 ± 0.3 at 89 days post transplantation). It is possible that pretreatment with GSI might have other mechanisms besides axonal regrowth, and could have a clinically meaningful effect and improve human iPSC-based transplantation for SCI.

Improved cell quality and safety, particularly with respect to the risk of tumor-like overgrowth, will be crucially important for any clinical use of hiPSC-NS/PCs. [@bib21] revealed that the photon counts measured by BLI analyses were significantly proportional to the number of the transplanted cells in vivo. [@bib17] indicated that some mice transplanted with 253G1 hiPSC-NS/PCs showed temporary motor function recovery for up to 47 days after transplantation; however, the photon counts of the transplanted cells increased more than 10-fold from its initial value, and these mice also developed tumor-like overgrowth and deterioration of motor function at 103 days after transplantation. Therefore, the photon counts measured by BLI analyses could be useful for the diagnosis for detecting tumor-like overgrowth in the mouse injured spinal cords. In the present study, the control group (i.e., the group without GSI pretreatment) showed a rapid increase in the photon count of the transplanted cells and improvements in hindlimb motor function, which subsequently deteriorated gradually upon long-term observations. However, in the GSI^+^ groups, the photon counts increased more slowly and reached a plateau after transplantation. Greater functional recovery was also observed, and was maintained at significantly higher levels compared with the control group. In addition, we previously reported that the size of the tumors formed by the transplanted hiPSC-NS/PCs in the injured spinal cord correlated with the proportion of Nestin^+^ cells in the graft ([@bib17]). The proportion of transplanted Nestin^+^ cells decreased from 10.7% ± 2.2% at 47 days to 7.5% ± 1.0% at 103 days after transplanting 201B7 hiPSC-NS/PCs, resulting in no tumor-like overgrowth. The proportion of Nestin^+^ cells increased from 19.6% ± 0.5% at 47 days to 33.1% ± 7.4% at 103 days after transplanting 253G1 hiPSC-NS/PCs. Therefore, we suggest that differentiation-resistant Nestin^+^ cells proliferated over time and formed tumors. However, the present study showed that the proportion of transplanted Nestin^+^ cells in the control group increased to 30.3% ± 1.6% at 89 days after transplantation and resulted in tumor-like overgrowth, whereas the proportion of Nestin^+^ cells in the GSI^+^ group decreased to 5.3% ± 0.8% at 89 days after transplantation and did not show evidence of tumor-like overgrowth. The proportion of Ki-67^+^ cells in the control group was significantly increased to 17.9% ± 0.9% at 89 days after transplantation compared with the GSI^+^ group. Furthermore, the proportion of pan-ELAVL (Hu)^+^ neuronal cells in the GSI^+^ groups significantly increased to 51.0% ± 1.8% compared with the control group at 89 days after transplantation, although significant differences were not observed in glial differentiation. Most of the GSI-pretreated, transplanted βIII-tubulin^+^/HNA^+^ cell-derived neurons were co-localized with Bsn^+^ synaptic boutons of the host neurons, and hSyn^+^ boutons were apposed to βIII-tubulin^+^/HNA^−^ host mouse neurons. These findings indicate that the proportion of proliferating/undifferentiating cells increases over time and induces tumor-like overgrowth in the vertebral canal of the mice. Therefore, the motor functional recovery observed in the control group subsequently deteriorated gradually upon long-term observations. However, pretreatment with GSI differentiated nearly all of these cells into mature neurons, which were further integrated into the reconstructed host neuronal network, where they formed synapses and prevented tumor-like overgrowth, even in mice transplanted with the "bad" clone, after observations for long periods. Therefore, significantly greater motor functional recovery was maintained compared with the control group.

The activation of Notch1 has been found to contribute to the invasion and metastasis of cancer via the EMT. In addition, [@bib25] showed that the overexpression of *NOTCH1* induces the expression of *SNAIL*. In the present study, after GSI treatment the expression of *NOTCH1*, *SNAIL1*, and *SNAIL2* was downregulated in vitro compared with the control group. Furthermore, the proportion of Notch1^+^, activated Notch1^+^, and Snail^+^ cells was also significantly decreased after transplantation compared with the control group, which indicated that the presence of activated Notch1 on the transplanted cells reflected the γ-secretase-dependent activation of Notch1 in vivo. Therefore, the GSI pretreatment could reduce the acquisition of EMT and inhibit the activation of Notch1 and Snail, which induced the transplanted cells to undergo neuronal maturation without tumor-like overgrowth upon transplantation of hiPSC-NS/PCs for SCI. However, [@bib11] showed that other signaling molecules act as targets for GSI. Thus, we cannot rule out the possibility that the GSI-induced inhibition of other signaling pathways, such as the expression of EMT-related genes, contributed to these results.

Longer differentiation periods have been shown to decrease the incidence of tumors. Alternatively, the selection of more mature cells using fluorescence-activated or magnetic-activated cell sorting, introduction of suicide genes, and irradiation of cells before transplantation may also help inhibit tumor-like overgrowth. However, these methods require long periods and more expensive processes to prepare the donor cells. In contrast, GSI pretreatment is a simple and inexpensive method that could be useful for improving the safety of hiPSC-NS/PCs transplantation therapy in SCI.

In conclusion, we confirmed that the GSI-treated hiPSC-NS/PCs exhibited a reduced proportion of dividing cells and increased neuronal maturation in vitro, and prevented the tumor-like overgrowth of transplanted cells by inhibiting cell proliferation, thereby resulting in safe and long-lasting functional recovery in vivo. Pretreatment of hiPSC-NS/PCs with GSI can improve the safety of hiPSC-NS/PC transplantation therapy for SCI.

Experimental Procedures {#sec4}
=======================

Cell Culture, hiPSC-NS/PC-Derived NS/PC Formation Assay, Neuronal Differentiation Analyses, and Lentiviral Transduction {#sec4.1}
-----------------------------------------------------------------------------------------------------------------------

The cell culture, hiPSC-NS/PC-derived NC/PC formation assay, neuronal differentiation analyses of several human iPSCs, and lentiviral transduction of neurospheres were performed as previously described ([@bib16], [@bib17], [@bib22]). In brief, three hiPSC-NS/PCs lines were dissociated and infected with a lentivirus expressing ffLuc, a firefly luciferase fusion protein under the control of the EF promoter, to enable the detection of transplanted cells through their strong bioluminescent ffLuc signals in live SCI mice and in fixed spinal cord sections. Detailed methods are described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Treatment of hiPSC-NS/PCs with GSI {#sec4.2}
----------------------------------

One of the small-molecule GSIs, N-\[N-(3,5-difluorophenacetyl)-l-alanyl\]-S-phenylglycine t-butyl ester (DAPT; Sigma-Aldrich), is a potent nontransition-state analog inhibitor of γ-secretase that is thought to interact with the same active site between presenilin-1 heterodimers in γ-secretase complexes. DAPT was dissolved in DMSO at a final concentration of 10 μM. The highest concentration of this molecule that effectively inhibited the division of hiPSC-NS/PCs without precipitating in culture medium or producing toxic effects was determined in preliminary experiments. The hiPSC-NS/PCs were cultured in vitro with GSI for 1 day in the GSI-1d group, 4 days in the GSI-4d group, and without GSI in the control group. For the neuronal differentiation, proliferation, and cell transplantation assays, the hiPSC-NS/PCs were used after the fifth passage.

Flow Cytometric Analyses {#sec4.3}
------------------------

In the cell-cycle analyses, the hiPSC-NS/PCs were dissociated into single cells and double immunofluorescence staining was performed with the Click-iT Plus EdU Flow Cytometry Assay Kit (Life Technologies). In the apoptosis analyses, double immunofluorescence staining was performed using the primary antibodies anti-allophycocyanin (APC)-labeled annexin V (561012) and 7-amino-actinomycin D (7-AAD, 559925) (BD Biosciences). The cells were stained with a mixture of these primary antibodies for 15 min at 37°C. Detailed methods are described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Microelectrode Array {#sec4.4}
--------------------

The MEA was performed as previously described ([@bib13]), and detailed methods are provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

DNA Microarray Analyses {#sec4.5}
-----------------------

DNA microarray analyses were performed as previously described ([@bib24]), and detailed methods are provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. GO accessions are listed and shown in [Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

qRT-PCR {#sec4.6}
-------

RNA isolation and RT-PCR were performed as previously described ([@bib16], [@bib17], [@bib22]), and detailed protocols are provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

SCI Animal Model and hiPSC-NS/PC Transplantation {#sec4.7}
------------------------------------------------

Contusive SCI was induced at the level of the tenth thoracic spinal vertebra in the spinal cords of adult female NOD-SCID mice. Nine days after SCI, hiPSC-NS/PCs that had been pretreated with or without GSI (5 × 10^5^ cells/2 μL) were transplanted into the lesion epicenter of each mouse. All experiments were performed in accordance with the Guidelines for the Care and Use of Laboratory Animals of Keio University (Assurance No. 13020) and the NIH Guide for the Care and Use of Laboratory Animals. Detailed methods are provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Histological Analysis {#sec4.8}
---------------------

Histological analyses were performed at 89 days after transplantation. Spinal cord sections were histologically evaluated by H&E staining and immunohistochemistry (IHC). Detailed protocols are provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Behavioral Analyses {#sec4.9}
-------------------

The motor function of each mouse in the PBS group, the control group, and the GSI^+^ group was evaluated weekly for up to 98 days after injury using the BMS scores ([@bib1]). Detailed methods are provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Statistical Analysis {#sec4.10}
--------------------

All data are reported as mean ± SEM. A Wilcoxon rank-sum test was used to evaluate the differences between groups with respect to the BLI analyses, H&E staining, and IHC results. One-way ANOVA followed by the Tukey-Kramer test for multiple comparisons was used to evaluate the differences in the following: number of living cells; sphere size; flow cytometric analyses of the cell cycle/apoptosis assays; neuronal differentiation analyses; MEA; DNA microarray analyses; RT-PCR gene expression profile analyses; and the rotarod and DigiGait results. Two-way repeated-measures ANOVA tests followed by the Tukey-Kramer test were used for the BMS analyses. p Values of \<0.05 or \<0.01 were considered to indicate statistical significance.
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====================
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Accession Numbers {#app1}
=================

The DNA microarray data have been submitted to the NCBI Gene Expression Omnibus under accession number GEO: [GSE76556](ncbi-geo:GSE76556){#intref0010}.
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![Proliferation of hiPSC-NS/PCs Treated with or without GSI\
(A) Number of living cells counted in ten separate fields using a microscope and compared among each group (n = 5 independent experiments).\
(B) Micrographs showing representative hiPSC-NS/PC aggregates for each group and cell line. Scale bars, 200 μm.\
(C) Size of hiPSC-NS/PCs measured in ten separate fields using a microscope and compared among each group (n = 5 independent experiments).\
(D) Cell-cycle analyses of hiPSC-NS/PCs performed using flow cytometry. Representative dot plots are shown for each group.\
(E) Histograms show the relative distribution of hiPSC-NS/PCs across the different cell cycle phases under self-renewing conditions (n = 5 independent experiments).\
(F) Analyses of hiPSC-NS/PC apoptosis performed using the annexin V/7-AAD apoptosis assay. The histograms show the relative distribution of hiPSC-NS/PCs across the different phases (n = 5 independent experiments).\
^∗^p \< 0.05, ^∗∗^p \< 0.01, and not significant (N.S.) according to one-way ANOVA with the Tukey-Kramer test. Data are presented as means ± SEM.](gr1){#fig1}

![Neuronal Differentiation and Neuronal Maturation of hiPSC-NS/PCs Treated with or without GSI\
(A and B) hiPSC-NS/PCs (with or without GSI treatment) dissociated into single cells, seeded on coverglasses, and immunostained for Ki-67 (cell proliferation marker) and Nestin (a neural stem cell marker). The nuclei were stained with Hoechst 33258. The micrographs show representative staining results for each group. Scale bars, 50 μm.\
(C and D) Histograms showing the percentage of Ki-67^+^ and Nestin^+^ cells (n = 5 independent experiments).\
(E and F) Fourteen days after neuronal induction, the hiPSC-NS/PCs were immunostained for βIII-tubulin (a neuron marker), GFAP (an astrocyte marker), and CNPase (an oligodendrocyte marker). The nuclei were stained with Hoechst 33258. The micrographs show representative staining results for each group. Scale bars, 50 μm.\
(G--I) Histograms showing the percentage of βIII-tubulin^+^, GFAP^+^, and CNPase^+^ cells (n = 5 independent experiments).\
(J) Daily analyses of neuronal maturation using MEA, which measures the active electrodes in each group (n = 5 independent experiments).\
^∗^p \< 0.05, ^∗∗^p \< 0.01, and not significant (N.S.) according to one-way ANOVA with the Tukey-Kramer test. Data are presented as means ± SEM.](gr2){#fig2}

![DNA Microarray and RT-PCR Analyses of GSI-Treated hiPSC-NS/PCs\
(A) Venn diagrams showing the human genes with decreased expression in each group of GSI-treated 253G1 hiPSC-NS/PCs. Color key: red, 36 genes with decreased expression in the GSI-1d group; blue, 213 genes with decreased expression in the GSI-4d group; purple, 61 genes with decreased expression in both groups (n = 3 independent experiments).\
(B) Venn diagrams showing the human genes with increased expression in each group of GSI-treated 253G1 hiPSC-NS/PCs. Color key: red, 5 genes with increased expression in the GSI-1d group; blue, 94 genes with increased expression in the GSI-4d group; purple, 53 genes with increased expression in both groups (n = 3 independent experiments).\
(C) Venn diagrams showing the human genes with decreased expression in the GSI-1d and GSI-4d group of 836B3 hiPSC-NS/PCs. Color key: red, 23 genes with decreased expression in the GSI-1d group; blue, 37 genes with decreased expression in the GSI-4d group; purple, 26 genes with decreased expression in both groups (n = 3 independent experiments).\
(D) Venn diagrams showing the human genes with increased expression in the GSI-1d and GSI-4d groups of 836B3 hiPSC-NS/PCs. Color key: red, 1 gene with increased expression in the GSI-1d group; blue, 70 genes with increased expression in the GSI-4d group; purple, 7 genes with increased expression in both groups (n = 3 independent experiments).\
(E and F) (E) Lists showing the downregulated and (F) upregulated genes compared with control and GSI-1d and GSI-4d groups for each cell line using DNA microarrays (fold change \>2.0).\
(G) qRT-PCR analyses of known EMT-related genes in the GSI-1d and GSI-4d groups compared with the control group (equal to 1). The data were normalized to the reference *GAPDH* levels (n = 3 independent experiments). ^∗^p \< 0.05 and ^∗∗^p \< 0.01 according to one-way ANOVA with the Tukey-Kramer test. Data are presented as means ± SEM.\
See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![Long-Term Observation after Transplantation of GSI-Pretreated 253G1 hiPSC-NS/PCs\
(A) Quantitative analyses of the photon counts derived from the transplanted cells until 89 days post transplantation (control group, n = 10 mice; GSI^+^ group, n = 10 mice).\
(B) Representative images of mice at 0, 14, 28, 56, and 89 days after transplantation of 253G1 hiPSC-NS/PCs that were pretreated with or without GSI.\
(C) Representative H&E-stained images of the spinal cord from each group at 89 days after transplantation. Scale bars, 1,000 μm.\
(D) Representative immunohistological images of HNA^+^ cells showing a graft from each group at 89 days after transplantation. Scale bars, 1,000 μm.\
(E) Graft volumes of hiPSC-NS/PCs were measured and estimated for each group of SCI at 89 days after transplantation (control group, n = 10 mice; GSI^+^ group, n = 10 mice).\
(F) Representative images of the immunohistochemical staining show the results for each group. The HNA^+^ transplanted cells were stained with Ki-67, Nestin, pan-ELAVL (Hu), GFAP, and APC. Scale bar, 20 μm.\
(G) Percentages of cell-type-specific, marker-positive cells among the HNA^+^ transplanted cells at 89 days after transplantation (control group, n = 10 mice; GSI^+^ group, n = 10 mice).\
^∗^p \< 0.05, ^∗∗^p \< 0.01, and not significant (N.S.) according to one-way ANOVA with the Tukey-Kramer test (G) or Wilcoxon rank-sum test (A and E). Data are presented as means ± SEM.](gr4){#fig4}

![Level of Notch and EMT Activation in the Transplanted Cells Following Long-Term Observations In Vivo\
(A--C) Representative images of immunohistochemical staining show the results for each group. The HNA^+^ transplanted cells were stained with Notch1, activated Notch1, and Snail. Scale bars, 20 μm.\
(D--F) Histograms showing the percentages of cell-type-specific, marker-positive cells among the HNA^+^ transplanted cells at 89 days after transplantation (control group, n = 10 mice; GSI^+^ group, n = 10 mice). ^∗∗^p \< 0.01 according to the Wilcoxon rank-sum test. Data are presented as means ± SEM.](gr5){#fig5}

![Long-Term Motor Function Analyses after Transplantation of GSI-Pretreated hiPSC-NS/PCs\
(A) Comparison of the BMS scores among the PBS, control, and GSI^+^ groups. Motor function in the hind limbs was assessed weekly for up to 89 days after transplantation using the BMS score (PBS group, n = 10; control group, n = 10; GSI^+^ group, n = 10 mice).\
(B) Comparison of the rotarod test among the PBS, control, and GSI^+^ groups. The rotarod test was performed at 89 days after transplantation. Histograms show the total run time (PBS group, n = 10; control group, n = 10; GSI^+^ group, n = 10 mice).\
(C) Comparison of the stride lengths among the PBS, control, and GSI^+^ groups. Treadmill gait analyses were performed at 89 days after transplantation using the DigiGait system. Histograms show the stride length (PBS group, n = 10; control group, n = 10; GSI^+^ group, n = 10 mice).\
^∗^p \< 0.05, ^∗∗^p \< 0.01, and not significant (N.S.) according to two-way repeated-measures ANOVA with the Tukey-Kramer test (A) or one-way ANOVA with the Tukey-Kramer test (B and C). Data are presented as means ± SEM.](gr6){#fig6}

![Long-Term Observations after Transplantation of GSI-Pretreated 201B7 hiPSC-NS/PCs\
(A) Quantitative analyses of the photon counts derived from the transplanted cells until 89 days post transplantation (control group, n = 10 mice; GSI^+^ group, n = 10 mice).\
(B) Representative images of mice at 0, 14, 28, 56, and 89 days after transplantation of 201B7 hiPSC-NS/PCs that were pretreated with or without GSI.\
(C) Representative H&E-stained images of the spinal cords from each group at 89 days after transplantation. Scale bars, 1,000 μm.\
(D) Representative immunohistological images of HNA^+^ cells, showing a graft from each group at 89 days after transplantation. Scale bars, 1,000 μm.\
(E) Graft volumes of the hiPSC-NS/PCs were measured and estimated for each group of SCI model animals at 89 days after transplantation (control group, n = 10 mice; GSI^+^ group, n = 10 mice).\
(F) Comparison of the BMS scores among the PBS, control, and GSI^+^ groups. Motor function in the hind limbs was assessed weekly for up to 89 days after transplantation using the BMS score (PBS group, n = 10; control group, n = 10; GSI^+^ group, n = 10 mice).\
(G) Comparison of the rotarod test among the PBS, control, and GSI^+^ groups. The rotarod test was performed at 89 days after transplantation. Histograms show the total run time (PBS group, n = 10; control group, n = 10; GSI^+^ group, n = 10 mice).\
(H) Comparison of the stride lengths among the PBS, control, and GSI^+^ groups. Treadmill gait analyses were performed at 89 days after transplantation using the DigiGait system. Histograms show the stride lengths (PBS group, n = 10; control group, n = 10; GSI^+^ group, n = 10 mice).\
^∗^p \< 0.05 and not significant (N.S.) according to the Wilcoxon rank-sum test (A and E), two-way repeated-measures ANOVA with the Tukey-Kramer test (F), or one-way ANOVA with the Tukey-Kramer test (G and H). Data are presented as means ± SEM.](gr7){#fig7}
